Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:42:24 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



V:NGEN - Nervgen Pharma Corp. - http://www.nervgen.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NGEN - V  1.52.10·2.131.32.11+0.094.5140.12882632.05  2.16  2.043.98  1.5015:57:47Apr 2515 min RT 2¢
TSX-V - V1.52.10·2.131.32.11+0.094.583.41721432.05  2.16  2.043.98  1.5015:57:0215 min
NEO ATS - U 2.13+0.115.415.131302.07  2.16  2.0615:47:3015 min
Alpha - A 2.11+0.094.524.651222.09  2.15  2.0615:57:4715 min
Omega - O 2.12+0.105.02.1432.10  2.12  2.1014:02:0915 min
Pure - P 2.09+0.073.51.0212.09  2.09  2.0913:26:4215 min
Chi-X - X 2.135+0.1155.72.55192.10  2.135  2.05515:20:3815 min
CX2 - H 2.135+0.1155.74.69112.07  2.135  2.0515:20:3815 min
CXD - D 2.14+0.125.94.18132.08  2.15  2.0615:47:3015 min
TriAct - M 2.022.7521    Sep 04-2015 min

Recent Trades - Last 10 of 263
Time ETExPriceChangeVolumeBuyerSellerMarkers
15:57:47A2.110.092,80079 CIBC79 CIBCK
15:57:47M2.110.092679 CIBC79 CIBCE
15:57:17A2.110.0910079 CIBC79 CIBCK
15:57:08A2.110.0910079 CIBC79 CIBCK
15:57:02V2.110.0910079 CIBC79 CIBCK
15:56:56V2.110.094001 Anonymous79 CIBCK
15:56:56V2.110.099001 Anonymous79 CIBCK
15:56:56V2.110.0920079 CIBC79 CIBCK
15:56:56V2.110.091,2001 Anonymous79 CIBCK
15:56:56V2.110.092002 RBC79 CIBCK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-04-25 12:29C:NGEN2.09News ReleaseNervgen Pharma hires Russo Partners for PR
2024-04-18 00:17C:NGEN1.98SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2024-04-18 00:17C:NGEN1.98SEDAR MD & ASEDAR MD & A
2024-04-17 14:20C:NGEN2.02News ReleaseNervgen Pharma's Dec. 31 cash at $11.7-million
2024-04-03 20:43C:NGEN2.34Prospectus ApprovedNervgen Pharma prospectus offering
2024-03-28 13:21C:NGEN2.18News ReleaseNervgen Pharma closes $23.01-million bought deal
2024-03-22 07:38C:NGEN2.49Resume TradingNervgen Pharma resuming at the open
2024-03-21 16:12C:NGEN2.49News ReleaseNervgen Pharma arranges $20-million offering
2024-03-21 15:51C:NGEN2.55Halt TradingNervgen Pharma halted at 12:43 p.m. PT
2024-02-20 17:47C:NGEN3.32News ReleaseNervgen grants options to buy shares
2024-02-15 13:06C:NGEN3.01News ReleaseNervgen to complete NVG-291 enrolment in Q2 2024
2023-11-09 14:25C:NGEN1.96News ReleaseNervgen Pharma's Sept. 30 cash at $14.8-million
2023-11-09 10:12C:NGEN1.96SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-09 10:12C:NGEN1.96SEDAR Interim MD & ASEDAR Interim MD & A
2023-10-23 11:30C:NGEN1.79News ReleaseNervgen receives fast-track designation for NVG-291
2023-10-17 13:01C:NGEN1.75News ReleaseNervgen appoints Ruffolo as director
2023-09-25 09:56C:NGEN2.05News ReleaseNervgen doses first patient in spinal cord injury trial
2023-08-09 15:25C:NGEN1.85News ReleaseNervgen cash and investments at $16.1M at June 30
2023-08-09 08:28C:NGEN1.85SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-08-08 11:44C:NGEN1.85News ReleaseNervgen receives IRB OK for NVG-291 trial